Abstract
Receptor tyrosine kinases (RTKs) are critical for normal cell growth, differentiation, and development, but they contribute to various pathological conditions when disrupted. Activation of RTKs stimulates a plethora of pathways, including the ubiquitylation and endocytosis of the receptor itself. Although endocytosis terminates RTK signaling, it has emerged as a requisite step in RTK activation of signaling pathways. We have discovered that the endocytic scaffolding protein intersectin (ITSN) cooperated with epidermal growth factor receptor (EGFR) in the regulation of cell growth and signaling. However, a biochemical link between ITSN and EGFR was not defined. In this study, we demonstrate that ITSN is a scaffold for the E3 ubiquitin ligase Cbl. ITSN forms a complex with Cbl in vivo mediated by the Src homology (SH) 3 domains binding to the Pro-rich COOH terminus of Cbl. This interaction stimulates the ubiquitylation and degradation of the activated EGFR. Furthermore, silencing ITSN by RNA interference attenuated EGFR internalization as well as activation of the extracellular signal-regulated kinasemitogen-activated protein kinase pathway, thereby demonstrating the importance of ITSN in EGFR function. Given the cooperativity between ITSN and additional RTKs, these results point to an important evolutionarily conserved, regulatory role for ITSN in RTK function that is necessary for both signaling from receptors as well as the ultimate termination of receptor signaling.
Footnotes
-
This work was supported in part by the Intramural Research Program of the National Institutes of Environmental Health Sciences, National Institutes of Health, and by start-up funds from the Department of Pharmacology at the University of Illinois at Chicago.
-
ABBREVIATIONS: RTK, receptor tyrosine kinase; MAPK, mitogen-activated protein kinase; SH, Src homology; EGFR, epidermal growth factor receptor; TKB, tyrosine kinase binding; PRD, Pro-rich domain; EH, Eps15 homology; ITSN, intersectin; ERK, extracellular signal-regulated kinase; HEK, human embryonic kidney; HA, hemagglutinin; GST, glutathione transferase; EGF, epidermal growth factor; PBS, phosphate-buffered saline; siRNA, small interfering RNA; BSA, bovine serum albumin; YFP, yellow fluorescent protein; JNK, c-Jun NH2-terminal kinase; DS, Down syndrome.
-
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
- Received June 22, 2006.
- Accepted August 16, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|